The US Food and Drug Administration (USFDA) inspected Indoco's sterile manufacturing facility in Goa (Plant II) from 7 October to 15 October, 2019. The audit was concluded successfully.
The Inspection ended with 2 observations, neither of these are related to Data Integrity or the core Quality Management System and the Company will respond to the FDA within the stipulated time. The site continues to maintain its VAI status.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
